Login Register Subscribe
Current Issue


BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Valeant gives former CEO $9 million severance, consulting deal


(Reuters) – J. Michael Pearson, the former chief executive of Valeant Pharmaceuticals International Inc., will receive a $9 million severance payment and agreed to a consulting agreement worth hundreds of thousands of dollars, according to a document filed with regulators.

Mr. Pearson, who left Valeant May 2 after a year in which it had drawn scrutiny for its sharp drug price increases, financial relationship with a specialty pharmacy and accounting practices, is also eligible for a pro-rated performance bonus for 2016, the separation agreement document said.

He can earn $83,333 a month this year as a consultant and next year, the company agreed to pay him $15,000 per month for consulting services, plus expenses. If Valeant severs the consulting services, Mr. Pearson will still receive the payments that would have been due, the document said.

After that time, Mr. Pearson could be paid $3,750 per day for any consulting services. He also promised to cooperate with the company on providing information related to government inquiries.

Mr. Pearson, who was replaced by former Perrigo Co. CEO Joseph Papa, had led Valeant since 2008, driving its growth through serial acquisitions. Under his watch, the company's stock hit a high of $263.70 in August 2015 and fell as low as $25.27 in April 2016 due to doubts that the company could recover from its hefty debt load. It hit a year-low of $23.55 May 12, after he left.

Valeant announced Mr. Pearson's departure in March as activist investor William Ackman took a position on the company's board of directors.